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Fluoroquinolones are widely used because of their broad
spectrum of activity. Their benefit-risk profile needs
careful evaluation as they can induce T cell-dependent
reactions including Stevens-Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN). Here we present two
rare cases of SJS/TEN overlap syndrome and SJS caused
by levofloxacin. Case 1. A 70-year-old woman with a
history of chronic obstructive pulmonary disease was
treated with levofloxacin for acute bronchitis. After tak-
ing medications for 10 days she complained of general-
ized skin eruptions and mucosal erosions. On the day of
admission in the burn intensive care department 28% of
her body surface was covered by rash, blistering and epi-
dermal peeling; 65% of body surface presented dusky red
skin. Levofloxacin was stopped and our patient was trea-
ted with topical solution to keep the wounds moist, fluid
replacement, well balanced nutrition, systemic corticos-
teroids and intravenous immune globulin (IVIG). We
also administrated teicoplanin because of S. aureus
infection of central i.v. catheter confirmed by a positive
culture. She was subsequently treated with meropenem
because of a Klebsiella pneumoniae urinary tract infec-
tion. The main laboratory findings were: anemia, leuko-
cytosis and increased CRP levels. The diagnosis was
performed on the basis of clinical and histological fea-
tures. Gradually her symptoms improved and the epi-
dermal peeling also subsided. Case 2. A 72-year-old
woman was referred to our department with multiple
skin lesions involving more than 50 % of the total body
surface area occurred after 2 weeks of starting levofloxa-
cin treatment for pneumonia. She developed high fever
and had the appearance of a severe burn patient.
Laboratory analysis showed anaemia, leukocytosis,
hypoalbuminaemia and elevated procalcitonin and CRP.
The levofloxacin treatment was stopped immediately and
replaced with teicoplanin and meropenem. Subsequently
because of A. baumanii complex infection of the central
i.v. catheter she was treated also with colistin. Our man-
agement included IVIG treatment, intravenous glucocor-
ticoids, proper fluid balance, attention to nutritional
status and pain relief. The skin lesions healed within
3 weeks and the patient left our department in good gen-
eral condition.
Conclusions
Even if there are little published data on levofloxacin
TEN/SJS, this fluoroquinolone can be implicated in
these delayed ADR requiring early diagnosis and careful
monitoring.
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